Daily Bulletin


The Conversation

  • Written by The Conversation

Following on from my previous post about the misleadingly dubbed “pink Viagra”, the drug flibanserin, to treat low sexual desire in women, news was received today confirming approval of the drug by the Food and Drug Administration. The approval follows the recommendation of an advisory committee convened to assess the safety and efficacy of the drug. After a day of hearings on 4 June the advisory committee agreed to recommend approval but did so reluctantly, and with a number of concerns about the management of the potential risks.

Three members of the scientific advisory committee subsequently published a viewpoint article in the Journal of the American Medical Association. They explained that in the highly politically charged environment surrounding flibanserin it is difficult for the FDA to balance a number of issues:

Firstly, the Even the Score consumer advocacy campaign mobilised a groundswell of support, campaigning on the platform of gender equality in medicine.

Secondly, there were concerns about the validity of the outcome measure used in new evidence provided to the committee following two previously unsuccessful attempts to gain FDA approval. The usefulness of the outcome measure (retrospective recall of sexual satisfaction over a month), however, was not the focus of the committee discussions.

Thirdly, there was considerable speculation about the way the drug would be likely to be used in clinical practice, and the committee noted significant concerns about the risks associated with potential off-label use of the drug.

The scientific advisory committee clearly recommended approval reluctantly, and the authors of the JAMA article note that:

“The FDA regulates drug approval and marketing, not the practice of medicine. The Committee’s discussions about flibanserin and off-label use highlight the challenge that the FDA encounters when considering a product that may help a subpopulation of patients, but also has a risk-benefit profile that may make it unacceptable for broader use.”

Today’s FDA decision to approve flibanserin ends weeks of speculation but is not unexpected. The question now is how women, their partners, their doctors, and society in general will embrace this new option.

Disclosure

Jayne Lucke is the Director of the Australian Research Centre in Sex, Health and Society at La Trobe University. She receives funding from the Australian Research Council and the National Health and Medical Research Council. She has served as a Director of Family Planning Queensland and been Chief Investigator on an ARC Linkage Grant that involves cash and in-kind support from Family Planning New South Wales and Bayer Australia. The Australian Research Centre in Sex, Health and Society receives funding from diverse sources listed in the annual report available from the website: http://www.latrobe.edu.au/arcshs

Authors: The Conversation

Read more http://theconversation.com/the-drug-flibanserin-is-approved-for-the-treatment-of-low-sexual-desire-in-women-46335

Writers Wanted

Physical Therapist Talks About This New Massage Gun On The Block - The HYDRAGUN

arrow_forward

Too much information: the COVID work revolution has increased digital overload

arrow_forward

Ammonite: the remarkable real science of Mary Anning and her fossils

arrow_forward

The Conversation
INTERWEBS DIGITAL AGENCY

Politics

Prime Minister's Remarks to Joint Party Room

PRIME MINISTER: Well, it is great to be back in the party room, the joint party room. It’s great to have everybody back here. It’s great to officially welcome Garth who joins us. Welcome, Garth...

Scott Morrison - avatar Scott Morrison

Prime Minister Interview with Ben Fordham, 2GB

BEN FORDHAM: Scott Morrison, good morning to you.    PRIME MINISTER: Good morning, Ben. How are you?    FORDHAM: Good. How many days have you got to go?   PRIME MINISTER: I've got another we...

Scott Morrison - avatar Scott Morrison

Prime Minister Interview with Kieran Gilbert, Sky News

KIERAN GILBERT: Kieran Gilbert here with you and the Prime Minister joins me. Prime Minister, thanks so much for your time.  PRIME MINISTER: G'day Kieran.  GILBERT: An assumption a vaccine is ...

Daily Bulletin - avatar Daily Bulletin

Business News

Getting Ready to Code? These Popular and Easy Programming Languages Can Get You Started

According to HOLP (History Encyclopedia of Programing Languages), there are more than 8,000 programming languages, some dating as far back as the 18th century. Although there might be as many pr...

News Co - avatar News Co

Avoid These Mistakes When Changing up Your Executive Career

Switching up industries is a valid move at any stage in your career, even if you’re an executive. Doing so at this stage can be a lot more intimidating, however, and it can be quite difficult know...

News Co - avatar News Co

4 Costly Mistake To Avoid When Subdividing Your Property

As a property developer or landowner, the first step in developing your land is subdividing it. You subdivide the property into several lots that you either rent, sell or award to shareholders. ...

News Co - avatar News Co



News Co Media Group

Content & Technology Connecting Global Audiences

More Information - Less Opinion